Losartan Potassium Tablet, Film Coated
Product Images NDC 42708-152

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42708-152). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 152 30)

Label for Losartan Potassium Tablet USP, 50 mg film-coated tablets by QPharma, Inc. Contains 30 tablets. Instructions area for dosage, including number of tablets, frequency, and duration. Includes storage advice to keep container tightly closed and store at controlled room temperature. Marked as sample, not for sale, and Rx Only.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with primary endpoints over study months for Losartan potassium and Atenolol. The x-axis represents months of study (0 to 60), and the y-axis shows percentage of patients (0 to 16%). The graph highlights an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan potassium versus Atenolol.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over months of study between Atenolol and Losartan potassium. The x-axis represents study months from 0 to 66, and the y-axis shows percentage of patients from 0 to 8%. Losartan potassium shows a lower rate of stroke over time compared to Atenolol, with an indicated adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure showing primary endpoint events in demographic subgroups comparing Losartan Potassium and Atenolol. The chart displays event rates and hazard ratios with 95% confidence intervals across age, gender, race, ISH status, diabetes, and history of cardiovascular disease, for both primary composite and stroke (fatal/non-fatal) outcomes. Symbols vary in size proportional to sample size.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients experiencing an event over 48 months between Losartan Potassium and Placebo groups. The y-axis shows the percent patients with event, and the x-axis represents time in months. The Losartan potassium group shows lower event rates compared to placebo, with a risk reduction of 16.1% (p=0.022).*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular components, including a chlorinated biphenyl group, tetrazole ring with potassium ion, and a butyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.